Anti-Cancer Medicine

XGEVA Xgeva 120mg  injection is a trade name of denosumab and which belongs to type of monoclonal antibody. This drug is classified as a “bone-modifying agent”, it works as a RANK ligand (RANKL) inhibitor.  Xgeva 120mg  injection which attach and repairs only certain cells in the body and help to protect healthy cells from destroy. INDICATION Xgeva 120mg  injection is indicated for the treatment of Osteoporosis occur in men and women (menopause stage) (end of menopause/ change of life), whose have severe problem of fractures increased or who failed to other medication of osteoporosis. In adults and some adolescents with giant cell tumor of bone which cannot cured with surgery / surgery is not possible is treated with  Xgeva 120mg  injection. MECHANISM OF ACTION : Denosumab is decided to target RANKL (RANK ligand), a protein which act as the main signal to help bone removal/resorption. Some of the bone loss conditions, RANKL overcome the...

OLIMAB 60MG Description : Olimab 60mg injection which attack and damage only certain cells in the body and help to protect healthy cells from demolish. Olimab 60mg dose   is a trade name of denosumab. This medication is classified as a “bone-modifying agent”, it works as a RANK ligand (RANKL) inhibitor. Olimab Used For : Olimab 60mg is indicated to treat breast cancer in women whose taking certain treatment which make severe their risk of fractures and bone loss in men with prostate cancer. Olimab 60mg injection is indicated for the treatment of osteoporosis occur in and women (menopause stage) (end of menopause/ change of life), whose risk of fractures increased or who failed to other medication of osteoporosis. Mechanism Of Action : Denosumab is planning to aim RANKL (RANK ligand), a protein which work as the primary signal to help bone removal/resorption. In many bone loss conditions, RANKL overcome the body's natural defense against bone eradication. Denosum...

ALECENSA 150MG Description : Alecensa 150mg belongs to class of second generation oral drug which specifically prevents the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. Alecensa is a prescription drug which used under the guidance of doctor. It is part used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Indication : Alecensa 150mg is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Dosage Modification  Non- Small Cell Lung Cancer The usual dose is 600mg PO BID until disease progression or unacceptable Renal impairment patients dose is 450mg orally twice daily Alecensa is administrated with food. Mechanism : In nonclinical studies, Alectinib inhibits ALK phosphorylation and ALK-mediated activation of the downstream indicati...

PROLIA 60MG Description : Prolia 60mg injections which attack and damage only certain cells in the body and help to protect healthy cells from demolish. Prolia 60mg injections is a trade name of denosumab. This medication is classified as a “bone-modifying agent”, it works as a RANK ligand (RANKL) inhibitor. Indication : Prolia 60mg dose is indicated to treat breast cancer in women whose taking certain treatment which make severe their risk of fractures and bone loss in men with prostate cancer. Prolia 60mg injections is indicated for the treatment of osteoporosis occur in and women (menopause stage) (end of menopause/ change of life), whose risk of fractures increased or who failed to other medication of osteoporosis. Mechanism Of Action : Denosumab inhibits RANKL from activating its receptor, RANK, which is on the surface of osteoclasts and their messengers. Prohibition of the RANKL/RANK interplay prevents osteoclast formation, function, and survival, Hence...

OLIMAB 60MG Description :  Olimab 60mg tablets belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the inhibition and treatment of bone metastases. Chemically, it exists of 2 heavy and 2 light chains. Each light chain contains of 215 amino acids. Each heavy chain contains of 448 amino acids with 4 intramolecular disulfides. Prescribed : Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer.Treatment for patients having to increase bone mass in women at more risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.Treatment for patients having postmenopausal women with osteoporosis at high risk for fracture. Mechanism : Denosumab...

ALECENSA ALECENSA 150mg is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). DESCRIPTION Alecensa 150mg belongs to second generation oral drug which selectively prohibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is part used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Prohibitions of ALK prevents phosphorylation and following downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. MECHANISM OF ACTION Alectinib belongs tyrosine kinase inhibitor whichaims ALK and RET. In nonclinical studies, Alectinibprohibits ALK phosphorylation and ALK-mediated activation of the downstream signalling proteins STAT3 and AKT, and reduced tumor cell viability in multiple cell lines harbouring ALK fusions, amplificati...